Bio tech company updates — 5/24/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector saw fresh activity on May 22–24, 2026, headlined by Eli Lilly's deepened partnership with Samsung Biologics and a stark industry warning that Korea must act more aggressively as Chinese biotech competition intensifies. U.S. investment in the sector is rebounding, but experts caution that the benefits of the "biotech spring" will not be evenly distributed across nations.
Key Findings
-
Eli Lilly marks 150 years with expanded Korea investment, announcing a deepened partnership with Samsung Biologics and the launch of AI-driven drug discovery initiatives through its Songdo Gateway Labs.
-
Korea urged to act more aggressively as China emerges as a formidable competitor in global biotech, even as U.S. investment rebounds from the prolonged "biotech winter."
Details
Eli Lilly Deepens Ties with Samsung Bio, Launches Songdo Gateway Labs
Eli Lilly, celebrating its 150th anniversary, has announced a significant boost to its Korea investment, including a partnership with Samsung Biologics and the establishment of its Songdo Gateway Labs — an innovation hub focused on AI-driven drug discovery. Korea's Lilly unit is positioning the country as a key node in its global R&D network.
The move underscores continued confidence in Korea's contract development and manufacturing (CDMO) capabilities, particularly Samsung Biologics, which has become a globally recognized biologics manufacturer.
Experts Warn Korea Must Act Boldly as China Gains Ground
An interview published by The BioNews highlights a pivotal inflection point: while U.S. biotech investment is rebounding after a prolonged downturn, industry insiders are telling Korea it cannot afford to be complacent. China has emerged as a formidable biotech competitor, and the "spring" of renewed investment will not benefit all nations equally.
The report signals urgency for Korean biotech companies and policymakers to accelerate deal-making, clinical pipelines, and global market positioning before the window of opportunity narrows.
Sources
- Chosunbiz — Eli Lilly marks 150 years, boosts Korea investment and partners Samsung Bio:
- The BioNews — U.S. biotech investment rebounds, but Korea told to act more aggressively as China gains ground:
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
